Loading...
XPARTNG
Market cap96mUSD
Dec 24, Last price  
0.70EUR
Name

Transgene SA

Chart & Performance

D1W1MN
XPAR:TNG chart
P/E
—
P/S
77.46
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.06%
Rev. gr., 5y
-2.37%
Revenues
1m
-62.12%
2,501,0002,514,0005,546,00028,019,00013,949,00011,765,00014,112,00014,446,0003,928,0003,849,0002,490,0001,465,0002,346,0002,099,0001,335,0006,652,0002,981,0009,993,0003,126,0001,184,000
Net income
-22m
L-31.95%
-20,875,000-20,485,000-22,031,000-5,521,000-18,000,000-27,347,000-34,219,000-43,626,000-43,203,000-42,858,000-48,556,000-46,374,000-25,207,000-32,274,0008,026,000-21,360,000-18,450,000-20,004,000-32,810,000-22,328,000
CFO
-35m
L+70.77%
-18,214,000-19,109,000-19,538,000-2,073,000-23,387,000-18,720,000-24,929,000-44,162,000-51,294,000-50,185,000-54,236,000-45,152,000-33,585,000-35,370,000-28,381,000-22,413,000-28,742,000-31,943,000-20,303,000-34,671,000
Earnings
Mar 25, 2025

Profile

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
URL
https://www.transgene.fr
IPO date
Mar 25, 1998
Employees
146
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,184
-62.12%
3,126
-68.72%
9,993
235.22%
Cost of revenue
62,994
67,557
68,360
Unusual Expense (Income)
NOPBT
(61,810)
(64,431)
(58,367)
NOPBT Margin
Operating Taxes
(6,450)
6
468
Tax Rate
NOPAT
(55,360)
(64,437)
(58,835)
Net income
(22,328)
-31.95%
(32,810)
64.02%
(20,004)
8.42%
Dividends
Dividend yield
Proceeds from repurchase of equity
34,129
BB yield
Debt
Debt current
1,240
1,192
1,395
Long-term debt
1,274
3,706
6,179
Deferred revenue
23
841
Other long-term liabilities
19,546
14,533
12,741
Net debt
(14,499)
(1,178)
(19,109)
Cash flow
Cash from operating activities
(34,671)
(20,303)
(31,943)
CAPEX
(2,746)
(1,535)
(686)
Cash from investing activities
34,572
20,272
16,793
Cash from financing activities
11,369
(1,477)
15,772
FCF
(48,407)
(72,409)
(57,020)
Balance
Cash
15,666
26,826
49,569
Long term investments
1,347
(20,750)
(22,886)
Excess cash
16,954
5,920
26,183
Stockholders' equity
(55,334)
(32,972)
(232)
Invested Capital
91,749
84,210
80,395
ROIC
ROCE
EV
Common stock shares outstanding
100,590
99,502
91,112
Price
Market cap
EV
EBITDA
(60,238)
(62,745)
(55,846)
EV/EBITDA
Interest
168
804
464
Interest/NOPBT